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337Abstracts
ization, and discount rate, were undertaken. RESULTS: In the
ﬁrst admission to perform PCI, the medical cost of the SES
patient was approximately 0.16m Japanese Yen higher than that
of the BMS patient. However, the expected three-year cumula-
tive medical cost per patient to be approximately 0.35m Yen
lower in the SES patient (2.07m Yen) than in the BMS patient
(2.43m Yen) because the revascularization rate was lower in the
SES patient. Extensive sensitivity analyses conﬁrmed that the
economic advantage of SES over BMS was quite robust. CON-
CLUSIONS: We concluded that the use of SES is likely to be a
cost-saving option as compared with BMS implantation within
the context of the Japanese health care system. Prospective eco-
nomic studies with long follow-up are needed to conﬁrm our
simulation results.
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OBJECTIVES: There are no published “real world” data for
costs of drug-eluting stenting procedures with the TAXUS 
Paclitaxel-Eluting Stent System. Whether Medicare payments
sufﬁciently cover costs of cases with comorbidities has not 
been investigated. METHODS: We analyzed resource utilization
data from ARRIVE, a prospective, multicenter, community-
hospital-based single arm US registry capturing 2590 consecu-
tive patients treated with the TAXUS stents at 50 sites. 
Procedural costs were calculated for subgroups with comorbidi-
ties of diabetes, renal disease, multivessel disease, congestive
heart failure, left main disease, acute myocardial infarction (MI),
and combinations of above conditions. Medical devices were
priced using 2004 national average prices, and procedural med-
ications using 2004 average wholesale prices. Hospitalization
costs were calculated using the 2003 MedPAR ﬁles, adjusted to
2004 costs. RESULTS: As shown in the table below, patients
with one or more comorbid conditions on average had higher
resource utilization and costs, ranging from $16,077 for left
main disease to $27,116 for renal disease (largely driven by the
length of stay). CONCLUSIONS: Stenting cases with severe
comorbidities incur higher costs than overall average. Average
Medicare payments in 2003 were $17,441 for patients with MI
(DRG 526) and $13,999 without MI (DRG 527). Clearly MI is
not the only comorbid condition that drives high inpatient costs.
The current DRG structure is not giving fair payments for
patients with certain high-cost comorbidities. 
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OBJECTIVES: Symptomatic intracranial atherosclerosis (IA) has
an annual stroke risk of 5%–20%. The study objectives were: 1)
to assess economics of existing and emerging IA stenting (IAS)
technologies; and 2) estimate the effect of IAS versus anti-platelet
therapy (APL) on stroke risk, overall survival (OS), quality-
adjusted life years (QALYs), costs, and cost-utility (CU).
METHODS: A Markov model was developed to compare IAS
with APL from a US perspective in patients with symptomatic
IA. The model included the following parameters: 1) procedural
complications; 2) restenosis rates; 3) stroke rates of patent or
stenosed vessels; 4) mortality after stroke; 5) utilities; and 6)
costs of procedure, strokes, and unrelated future resource use.
Procedural outcomes of the current model are based on litera-
ture ﬁndings. Costs in $US 2004 and beneﬁts were discounted
at ﬁxed annual rate of 3%. Sensitivity analysis was also per-
formed on the above parameters. RESULTS: With IAS, 74% of
patients had patent vessel at six-months; 18% of patients expe-
rienced restenosis by 12 months, 11.3% of patients had a pro-
cedural complication (3.3% stroke, 6.3% non-stroke, 1.7%
death). Stroke risk is predicted to decline from 7.3%/yr from the
stenosed, target vessel to 0.5%/yr with patent vessel; and 5%/yr
stroke risk in non-target vessels. Over ﬁve years, stroke risk is
predicted to decline from 44% with APL to 31% for IAS. OS
thus is expected to increase by 0.33 years, and 0.24 QALYs. The
average cost per IAS procedure is $9,731, with a predicted
$8,366 reduction in stroke-related costs and cost-utility of IAS
vs APL of $19,963 over a 10-year time horizon. CONCLU-
SIONS: The cost-effectiveness model shows that IA stenting is
predicted to substantially reduce stroke rate, increase overall sur-
vival and QALY relative to antiplatelet therapy. The projected
CU ratio is considered within acceptable adoption ranges in the
US.
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OBJECTIVE: To evaluate the long-term outcomes of drug-
eluting stents in comparison to bare-metal stents in conventional
Renal Multivessel 
Overall Diabetes Disease Disease 
(n = 1968) (n = 586) (n = 48) (n = 707)
Proc. 
Duration 54.6 55.4 68.2 60.8
(min)
Stents 
implanted 1.7 1.71 1.65 1.82
Gp IIb/IIIa 35.3% 35.1% 28.4% 33.3%
Inhibitor
Length of 2.7 3 7.4 3
stay (days)
Total Cost $15,858 $16,641 $27,116 $17,131
Congestive Left Main >=1 
Heart Failure Disease Acute MI comorbidities
(n = 239) (n = 109) (n = 181) (n = 1223) 
Proc. 
Duration 60.4 64.4 57.1 57.0 
(min)
Stents 
implanted 1.7 1.7 1.7 1.7 
Gp IIb/IIIa 33.9% 41.6% 46.6% 34.7% 
Inhibitor
Length of 3.7 2.6 3.6 2.9 
stay (days)
Total Cost $18,520 $16,077 $18,162 $16,408
